Candel Therapeutics Inc. (CADL)
| Bid | 4.07 |
| Market Cap | 305.25M |
| Revenue (ttm) | 1M |
| Net Income (ttm) | -22.14M |
| EPS (ttm) | -0.66 |
| PE Ratio (ttm) | -8.42 |
| Forward PE | -6.01 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 7.01 |
| Volume | 531,600 |
| Avg. Volume (20D) | 812,198 |
| Open | 5.46 |
| Previous Close | 5.41 |
| Day's Range | 5.46 - 5.76 |
| 52-Week Range | 3.79 - 14.60 |
| Beta | -0.93 |
| Ex-Dividend Date | n/a |
About CADL
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CADL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
5 days ago · proactiveinvestors.com
Candel trial shows promise for gene therapy in prostate cancerCandel Therapeutics Inc (NASDAQ:CADL) said Monday that its experimental treatment CAN-2409 significantly extended the time patients lived without their prostate cancer returning, according to results ...
1 month ago · proactiveinvestors.com
Candel Therapeutics adds immunotherapy expert to Research Advisory BoardCandel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on viral immunotherapies, announced the appointment of Dr Carl June to its Research Advisory Board. Dr June is...
1 month ago · proactiveinvestors.com
Candel Therapeutics secures RMAT for prostate cancer – ICYMICandel Therapeutics Inc (NASDAQ:CADL) CEO talked with Proactive earlier this week about the company's recent achievements in oncology drug development, with a strong focus on its gene therapy programs...
1 month ago · proactiveinvestors.com
Candel Therapeutics advances toward prostate cancer therapy filing after trial successCandel Therapeutics Inc (NASDAQ:CADL) said on Thursday it plans to seek US approval for its lead cancer drug CAN-2409 in late 2026, after a key Phase 3 prostate cancer trial succeeded and the FDA gran...
2 months ago · proactiveinvestors.com
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409Candel Therapeutics Inc (NASDAQ:CADL) announced that the European Medicines Agency (EMA) has granted Orphan Designation to its investigational immunotherapy CAN-2409 for the treatment of pancreatic ca...
2 months ago · proactiveinvestors.com
Candel Therapeutics expands Russell Index presence following 2025 reconstitutionCandel Therapeutics Inc (NASDAQ:CADL) has announced its inclusion in several value-oriented Russell indexes as part of the 2025 Russell US Indexes annual reconstitution. The changes became effective w...